Full Press Release Details
SELECT SEGMENT INFORMATION
QUARTERS AND FISCAL YEARS TO DATE 2025 and 2024
| Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||
| March 29, 2025 | June 28, 2025 | September 27, 2025 | December 31, 2025 | December 31, 2025 | ||||||||||||||||||||
| Net Sales | ||||||||||||||||||||||||
| Self Care | $ | 614.3 | $ | 598.6 | $ | 633.1 | $ | 687.6 | $ | 2,533.5 | ||||||||||||||
| Specialty Care | 199.1 | 233.1 | 191.2 | 176.0 | 799.3 | |||||||||||||||||||
| Infant Formula | 87.8 | 82.0 | 89.3 | 99.9 | 359.0 | |||||||||||||||||||
| Total Segments Net Sales | $ | 901.2 | $ | 913.6 | $ | 913.6 | $ | 963.4 | $ | 3,691.8 | ||||||||||||||
| All Other | 142.7 | 142.7 | 129.7 | 146.2 | 561.3 | |||||||||||||||||||
| Consolidated Net Sales | $ | 1,043.9 | $ | 1,056.3 | $ | 1,043.3 | $ | 1,109.6 | $ | 4,253.1 |
| Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||
| Net Sales | March 30, 2024 | June 29, 2024 | September 28, 2024 | December 31, 2024 | December 31, 2024 | |||||||||||||||||||
| Self Care | $ | 627.7 | $ | 600.5 | $ | 637.6 | $ | 688.6 | $ | 2,554.3 | ||||||||||||||
| Specialty Care | 208.7 | 220.2 | 188.3 | 179.5 | 796.6 | |||||||||||||||||||
| Infant Formula | 74.3 | 74.9 | 115.4 | 132.4 | 397.0 | |||||||||||||||||||
| Total Segments Net Sales | $ | 910.7 | $ | 895.6 | $ | 941.3 | $ | 1,000.4 | $ | 3,747.9 | ||||||||||||||
| All Other | 171.5 | 170.0 | 146.3 | 137.8 | 625.6 | |||||||||||||||||||
| Consolidated Net Sales | $ | 1,082.1 | $ | 1,065.5 | $ | 1,087.5 | $ | 1,138.3 | $ | 4,373.4 |
Note Amounts may not add or recalculate due to rounding.
SELECT SEGMENT INFORMATION
QUARTERS AND CALENDAR YEAR TO DATE 2025
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||
| Continuing Operations | March 29, 2025 | June 28, 2025 | September 27, 2025 | December 31, 2025 | December 31, 2025 | ||||||||||||||
| Segment adjusted operating income | |||||||||||||||||||
| Self Care | $ | 112.8 | $ | 93.8 | $ | 130.6 | $ | 135.3 | $ | 472.6 | |||||||||
| Specialty Care | 42.1 | 66.3 | 42.1 | 50.0 | 200.5 | ||||||||||||||
| Infant Formula | 10.6 | (12.2) | 14.6 | (3.4) | 9.6 | ||||||||||||||
| Total segment adjusted operating income | $ | 165.5 | $ | 147.9 | $ | 187.3 | $ | 181.9 | $ | 682.6 | |||||||||
| All Other | 21.0 | 25.7 | 22.5 | 24.2 | 93.4 | ||||||||||||||
| Unallocated | (39.9) | (38.5) | (36.4) | (38.9) | (153.7) | ||||||||||||||
| Consolidated adjusted operating income | $ | 146.6 | $ | 135.2 | $ | 173.4 | $ | 167.2 | $ | 622.3 |
Note Amounts may not add or recalculate due to rounding.
RECONCILIATION OF NON-GAAP MEASURES
SELECT CONSOLIDATED INFORMATION
QUARTERS AND CALENDAR YEAR TO DATE 2025
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||
| Consolidated Continuing Operations | March 29, 2025 | June 28, 2025 | September 27, 2025 | December 31, 2025 | December 31, 2025 | ||||||||||||||
| Reported Operating Income (Loss) | $ | 46.9 | $ | 45.4 | $ | 72.6 | $ | (1,287.2) | $ | (1,122.2) | |||||||||
| Pre-tax adjustments | |||||||||||||||||||
| Amortization expense related primarily to acquired intangible assets | 55.0 | 56.8 | 56.0 | 55.7 | 223.5 | ||||||||||||||
| Unusual litigation | 8.9 | 15.4 | 15.0 | 19.7 | 59.0 | ||||||||||||||
| Restructuring charges and other termination benefits | 29.4 | 8.7 | 20.9 | 13.0 | 71.9 | ||||||||||||||
| Impairment charges (1) | 3.1 | 1.5 | - | 1,358.5 | 1,363.1 | ||||||||||||||
| Infant formula remediation | 0.9 | - | - | - | 0.9 | ||||||||||||||
| Other (2) | 2.4 | 7.4 | 8.9 | 7.4 | 26.1 | ||||||||||||||
| Consolidated adjusted operating income | $ | 146.6 | $ | 135.2 | $ | 173.4 | $ | 167.2 | $ | 622.3 |
Note Amounts may not add or recalculate due to rounding.
(1) During the three months ended March 29, 2025, we determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million, inclusive of a goodwill impairment charge of $1.2 million. During the three months ended June 28, 2025, we determined the carrying value of our Prevacid branded product was impaired by $1.5 million. During the three months ended December 31, 2025, we determined the carrying value of our reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $1.3 billion and the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million.
(2) Other pre-tax adjustments for the three months ended March 29, 2025 are related to professional consulting fees for potential divestiture activity. Other pre-tax adjustments for the three months ended June 28, 2025 are primarily related to $4.5 million of accelerated depreciation as a result of our Nutrition Network Optimization Project and $2.8 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the three months ended September 27, 2025 includes $4.2 million of accelerated depreciation and a $1.6 million asset abandonment related to our Nutrition Network Optimization Project and $3.1 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the three months ended December 31, 2025 includes $3.8 million of professional consulting fees for potential divestiture activity and $3.2 million of accelerated depreciation.